Optimization of DNA immunization against human cytomegalovirus

Vaccine

Volumn 19, Issue 28-29, 2001, Pages 3972-3980

  Endresz V ^a   Burian K ^a   Berencsi, K ^b   Gyulai, Zs ^a   Kari, L ^b   Horton, H ^b   Virok, D ^a   Meric C ^c   Plotkin, S A ^c   Gonczol E ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b WISTAR INSTITUTE   (United States)

^c SANOFI PASTEUR   (France)

Author keywords

Cytomegalovirus; DNA immunization; DNA vaccines

Indexed keywords

ALPHA INTERFERON; BUPIVACAINE; CYTOMEGALOVIRUS ANTIBODY; DNA VACCINE; GLYCOPROTEIN B; KANAMYCIN; PLASMID VECTOR; PROTEIN SUBUNIT; VIRUS GLYCOPROTEIN; VIRUS PHOSPHOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN CYTOMEGALOVIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; VERO CELL;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BUPIVACAINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERFERON-ALPHA; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; PHOSPHOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; VIRAL MATRIX PROTEINS; VIRAL VACCINES;

EID: 0035898932     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00116-5     Document Type: Article

References (51)

1. Cytomegalovirus
2. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): Use of HCMV-recombinant vaccinia virus-infected cells in analysis of human neutralizing antibody response
3. High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant; the importance of the gB protein in HCMV-immunity
4. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity
5. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression
6. The human cytotoxic T lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity and T-cell receptor usage of pp65-specific CTL
7. Target structures of the CD8+-T-cell response to human cytomegalovirus: The 72-kilodalton major immediate-early protein revisited
8. Cytotoxic T lymphocyte (CTL) responses to HCMV pp65, IE1-exon4, gB, pp150, and pp28 in healthy individuals: Reevaluation of prevalence of IE1-specific CTL
9. Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune responses in human volunteers
10. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant
11. An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies
12. Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB
13. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate
14. The N-terminal 303 amino acids of the human cytomegalovirus envelope glycoprotein B (UL55) and the exon 4 region of the major immediate early protein 2 (UL123) induce a cytotoxic T-cell response
15. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne)
16. A canarypox vector expressing cytomegalovirus phosphoprotein 65 (pp65) induces long-lasting cytotoxic T cell responses in human cytomegalovirus (HCMV) seronegative volunteers
17. DNA vaccines: A new approach to immunization
18. DNA vaccination against persistent viral infection
19. DNA vaccines
20. Biological features of genetic immunization
21. DNA and RNA-based vaccines: Principles, progress and prospects
22. Induction of neutralizing antibody against human cytomegalovirus (HCMV) with DNA-mediated immunization of HCMV glycoprotein B in mice
23. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization
24. Direct DNA immunization of mice with plasmid DNA encoding the tegument protein pp65 (ppUL83) of human cytomegalovirus induces high levels of circulating antibody to the encoded protein
25. DNA immunization confers protection against murine cytomegalovirus infection
26. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65)
27. Gene gun-based nucleic acid immunization: Elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA
28. Superiority of intramuscular route and full length glycoprotein D for DNA vaccination against herpes simplex 2. Enhancement of protection by the co-delivery of the GM-CSF gene
29. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
30. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
31. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device
32. An improved plasmid DNA expression vector for direct injection into skeletal muscle
33. A rapid microneutralization assay for cytomegalovirus
34. Evaluation of tick-borne encephalitis DNA vaccines in monkeys
35. Gene inoculation generates immune responses against human immunodeficiency virus type 1
36. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen
37. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV
38. DNA inoculation with a plasmid vector carrying the hepatitis E virus structural protein gene induces immune response in mice
39. Stable incorporation of bacterial gene into adult rat skeletal muscle in vivo
40. Pharmacological enhancement of in vivo foreign gene expression in muscle
41. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 env antibody elicited by DNA priming and protein boosting
42. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation
43. Characterization of antibody responses to a Plasmodium falciparum blood-stage antigen induced by a DNA prime/protein boost immunization protocol
44. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate: Immune response elicited in a prime/boost protocol with the glycoprotein B subunit
45. Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response
46. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells
47. Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerate dendritic cell maturation from human peripheral blood mononuclear cells
48. Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages
49. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development
50. Interferons in melanoma
51. Interferon-alpha for viral hepatitis